metformin and mdv 3100

metformin has been researched along with mdv 3100 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
DeVere White, RW; Evans, CP; Gao, AC; Kung, HJ; Lara, PN; Nguyen, HG; Shi, XB; Tilki, D; Yang, JC1
Bi, G; Do, K; Geary, K; Jiang, J; Lan, W; Li, Y; Liu, G; Liu, Q; Tong, D; Xu, J; Zhang, D; Zhang, J; Zhang, Y1
Hill, J; McCabe, C; North, SA; Paulden, M; Usmani, N; Venner, P1
Armstrong, A; Beer, TM; Carles, J; Crumbaker, M; de Bono, J; Duggan, W; Fizazi, K; Gillessen, S; Hussain, M; Joshua, AM; Lin, P; Russell, D; Scher, HI; Sternberg, CN; Sugg, J; Tombal, B1

Reviews

1 review(s) available for metformin and mdv 3100

ArticleYear
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 170

    Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metformin; Nitriles; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome

2022

Other Studies

4 other study(ies) available for metformin and mdv 3100

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model.
    Oncogene, 2014, Sep-04, Volume: 33, Issue:36

    Topics: Androgen Receptor Antagonists; Animals; Autophagy; Benzamides; Cell Line, Tumor; Chloroquine; Clomipramine; Gene Expression Regulation, Neoplastic; Humans; Male; Metformin; Mice; Mice, SCID; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Signal Transduction; Xenograft Model Antitumor Assays

2014
Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT.
    Cell death & disease, 2017, 08-24, Volume: 8, Issue:8

    Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Interactions; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Hypoglycemic Agents; Male; Metformin; Mice; Mice, Nude; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; STAT3 Transcription Factor; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays

2017
Cost-effectiveness analysis of metformin with enzalutamide in the metastatic castrate-resistant prostate cancer setting.
    The Canadian journal of urology, 2019, Volume: 26, Issue:6

    Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Male; Markov Chains; Metformin; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome

2019